<html><head></head><body><h1>Gemtuzumab</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
<b>Chemical Name:</b> Methyl [(1R,4Z,8S,13E)-[8-[[2-O-[4-(acetylethylamino)-2,4-dideoxy-3-O-methyl-α-L-threo-pentopyranosyl]-4,6-dideoxy-4-[[[2,6-dideoxy-4-S-[4-[6-deoxy-3-O-methyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl]-4-thio-β-D-ribo-hexopyranosyl]oxy]amino]-β-D-glucopyranosyl]oxy]-13-[2-[[3-[[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazino]-1,1-dimethyl-3-oxopropyl]-dithio]ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]carbamate conjugate dimer disulfide with human-mouse monoclonal hP67.6 κ-chain anti-(human CD33 (antigen)) (human-mouse monoclonal hP67.6 γ4-chain, immunoglobulin G4<br/>
<b>CAS Number:</b> 220578-59-6<br/>
<b>Brands:</b> Mylotarg</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>
<li>
<p>Risk of hepatotoxicity, including hepatic veno-occlusive disease (VOD; also known as sinusoidal obstruction syndrome); may be life-threatening or fatal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatotoxicity under Cautions.)</p>
</li>
<li>
<p>Reported in patients receiving the drug as monotherapy or as part of a combination chemotherapy regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Monitor frequently for manifestations of hepatic VOD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Risk of hepatotoxicity, including hepatic veno-occlusive disease (VOD; also known as sinusoidal obstruction syndrome); may be life-threatening or fatal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatotoxicity under Cautions.)</p><p>Reported in patients receiving the drug as monotherapy or as part of a combination chemotherapy regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor frequently for manifestations of hepatic VOD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Antineoplastic agent; CD33-directed antibody-drug conjugate consisting of an anti-CD33 monoclonal antibody covalently linked to a cytotoxic calicheamicin derivative (<i>N</i>-acetyl-γ-calicheamicin).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Gemtuzumab</h2><h3>Acute Myeloid Leukemia (AML)</h3><p>Used in combination with daunorubicin and cytarabine for induction and consolidation therapy in adults with newly diagnosed CD33-positive de novo AML.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Subgroup analysis suggests possible lack of clinical benefit in patients with unfavorable cytogenetics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Decreased Efficacy in Patients with Unfavorable Cytogenetics under Cautions.)</p><p>Used alone (i.e., as single agent) for induction and continuation therapy in adults with newly diagnosed CD33-positive AML.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used as single-agent therapy for relapsed or refractory CD33-positive AML in adults and children ≥2 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Designated an orphan drug by FDA for treatment of AML.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Gemtuzumab Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>To minimize risk of infusion-related reactions in <i>adults</i>, premedicate with acetaminophen 650 mg and diphenhydramine hydrochloride 50 mg 1 hour prior to each infusion, followed by methylprednisolone 1 mg/kg (or equivalent) within 30 minutes prior to infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Infusion-related Effects under Cautions.)</p>
</li>
<li>
<p>To minimize risk of infusion-related reactions in <i>pediatric patients</i>, premedicate with acetaminophen 15 mg/kg (up to maximum dose of 650 mg), diphenhydramine hydrochloride 1 mg/kg (up to maximum dose of 50 mg), and methylprednisolone 1 mg/kg (or equivalent) 1 hour prior to each infusion; may administer additional doses of acetaminophen and diphenhydramine hydrochloride every 4 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>If WBC counts ≥30,000/mm<sup>3</sup>, cytoreduction prior to administration is recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Take appropriate measures to prevent tumor lysis syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>To minimize risk of infusion-related reactions in <i>adults</i>, premedicate with acetaminophen 650 mg and diphenhydramine hydrochloride 50 mg 1 hour prior to each infusion, followed by methylprednisolone 1 mg/kg (or equivalent) within 30 minutes prior to infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Infusion-related Effects under Cautions.)</p><p>To minimize risk of infusion-related reactions in <i>pediatric patients</i>, premedicate with acetaminophen 15 mg/kg (up to maximum dose of 650 mg), diphenhydramine hydrochloride 1 mg/kg (up to maximum dose of 50 mg), and methylprednisolone 1 mg/kg (or equivalent) 1 hour prior to each infusion; may administer additional doses of acetaminophen and diphenhydramine hydrochloride every 4 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If WBC counts ≥30,000/mm<sup>3</sup>, cytoreduction prior to administration is recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Take appropriate measures to prevent tumor lysis syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>For solution compatibility information, see Compatibility under Stability.</p><p>Administer by IV infusion using a 0.2-μm polyethersulfone inline filter.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Must reconstitute powder for injection and dilute to an appropriate concentration prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do <i>not</i> admix with or infuse simultaneously through the same IV line with other drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Protect drug from light during storage and administration; only the infusion container (syringe or bag) must be protected from light during infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Vials are intended for single use only; discard any partially used vials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prior to reconstitution, allow vials to stand at room temperature for approximately 5 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstitute vial containing 4.5 mg of gemtuzumab ozogamicin with 5 mL of sterile water for injection to provide a solution containing 1 mg/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Gently swirl vial to dissolve powder.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> shake.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstituted solution may contain small white to off-white, opaque to translucent, and amorphous to fiber-like particulates.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If not used immediately, may store reconstituted drug according to manufacturer's storage instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Storage under Stability.)</p><p>Withdraw appropriate volume of reconstituted solution and dilute to final concentration of 0.075–0.234 mg/mL prior to IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prepare final diluted solution in a syringe or IV bag depending on dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; For doses ≥3.9 mg, may prepare in either a syringe or infusion bag; for doses &lt;3.9 mg, must prepare in a syringe to reduce potential for drug adsorption.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gently invert infusion container to mix solution; do <i>not</i> shake.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediate administration recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If not used immediately, may store infusion solution according to manufacturer's storage instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Storage under Stability.) If diluted solution was previously refrigerated, bring to room temperature for 1 hour prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by IV infusion over 2 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Treatment consists of a single course of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pediatric patients ≥2 years of age: 3 mg/m<sup>2</sup> (up to a maximum dose of 4.5 mg) on days 1, 4, and 7 for one cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Follow recommendations for dosage modification in adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Full treatment course consists of 1–2 cycles of induction therapy and 2 cycles of consolidation therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3 mg/m<sup>2</sup> (up to maximum dose of 4.5 mg) on days 1, 4, and 7 in combination with daunorubicin and cytarabine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If complete remission not achieved, may consider a second induction cycle consisting of <i>only</i> daunorubicin and cytarabine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3 mg/m<sup>2</sup> (up to maximum dose of 4.5 mg) on day 1 in combination with daunorubicin and cytarabine for 2 cycles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer consolidation therapy 14 days after CBCs recover from previous cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If platelet counts do not recover to ≥100,000/mm<sup>3</sup> and ANC counts do not recover to &gt;500/mm<sup>3</sup> within 14 days after the planned start date of consolidation therapy, omit gemtuzumab ozogamicin from consolidation cycles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Full treatment course consists of 1 cycle of induction therapy and up to 8 cycles of continuation therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>6 mg/m<sup>2</sup> on day 1 followed by 3 mg/m<sup>2</sup> on day 8.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>2 mg/m<sup>2</sup> on day 1 of each 4-week cycle, up to 8 cycles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment consists of a single course of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>3 mg/m<sup>2</sup> (up to a maximum dose of 4.5 mg) on days 1, 4, and 7 for one cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If treatment-related toxicities occur, monitor CBCs and blood chemistries at least 3 times per week until resolution of the toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If thrombocytopenia or neutropenia occurs in patients receiving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine, discontinuance of gemtuzumab ozogamicin during consolidation therapy may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Combination Therapy for Newly Diagnosed CD33-positive AML under Dosage and Administration.)</p><p>If serum ALT and/or AST concentrations increase to &gt;2.5 times the ULN or total bilirubin concentrations &gt;2 times the ULN, interrupt therapy until ALT and AST recover to ≤2.5 times the ULN and total bilirubin concentrations recover to ≤2 times the ULN.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If therapy is withheld for &gt;2 days between sequential doses, omit scheduled dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If hepatic VOD or other severe hepatotoxicity occurs, discontinue therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If infusion-related reactions occur, interrupt infusion and institute appropriate treatment (e.g., acetaminophen, diphenhydramine, and/or methylprednisolone) and supportive care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Upon resolution of a mild or moderate infusion-related reaction, may resume infusion but consider reducing infusion rate by at least 50%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If the infusion-related reaction recurs, interrupt infusion again and follow same recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a severe or life-threatening infusion-related reaction (i.e., anaphylaxis, severe respiratory symptoms, clinically important hypotension) occurs, permanently discontinue therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If other severe or life-threatening nonhematologic toxicity occurs, interrupt therapy until toxicity improves to no more than mild in severity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If therapy is withheld for &gt;2 days between sequential doses, omit scheduled dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Pediatric patients ≥2 years of age: Maximum dose of 4.5 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Combination therapy with daunorubicin and cytarabine: Maximum dose of 4.5 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum dose of 4.5 mg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>No specific dosage recommendations at this time.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Cautions.)</p><p>No specific dosage recommendations at this time.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Cautions.)</p><p>No special dosage recommendations at this time.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Use under Cautions.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Gemtuzumab</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to gemtuzumab ozogamicin or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to gemtuzumab ozogamicin or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Hepatotoxicity, including life-threatening or fatal hepatic VOD, reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Boxed Warning.) Median time to onset 9 days (range: 2–298 days); generally occurs within 28 days following any dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of hepatic VOD is increased in patients receiving higher dosages (e.g., 9 mg/m<sup>2</sup> for 2 doses administered 14 days apart) as a single agent, those with preexisting moderate or severe hepatic impairment, and those receiving the drug before or after hematopoietic stem cell transplantation (HSCT).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>An interval of at least 2–3.5 months between the last dose of gemtuzumab ozogamicin and HSCT recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Closely monitor for manifestations of hepatic VOD (e.g., elevated aminotransferase and/or total bilirubin concentrations, hepatomegaly, rapid weight gain, ascites).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Liver function test abnormalities also reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Assess liver function tests (i.e., ALT, AST, total bilirubin, alkaline phosphatase) prior to each dose; more frequent monitoring may be necessary during the post-HSCT period in patients proceeding to HSCT following therapy with gemtuzumab ozogamicin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If liver function test abnormalities occur, monitor liver function tests and clinical manifestations of hepatotoxicity more frequently.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If hepatotoxicity occurs, temporary interruption of therapy or drug discontinuance may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatotoxicity under Dosage and Administration.)</p><p>If hepatic VOD occurs, discontinue drug and institute treatment according to standard practices.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Life-threatening or fatal infusion-related reactions (e.g., pyrexia, chills, hypotension, tachycardia, hypoxia, respiratory failure) reported, generally during or within 24 hours following an infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Premedicate with acetaminophen, an antihistamine (e.g., diphenhydramine), and a corticosteroid prior to each infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor patient during and for at least 1 hour following completion of infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also monitor vital signs frequently.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If manifestations of an infusion-related reaction occur, especially dyspnea, bronchospasm, or hypotension, immediately interrupt infusion and monitor patient until resolution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Provide appropriate treatment and supportive care; reduction in infusion rate or permanent discontinuance of therapy may be required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Infusion-related Effects under Dosage and Administration.)</p><p>Prolonged thrombocytopenia (platelet counts &lt;50,000/mm<sup>3</sup> lasting longer than 42 days in the absence of active disease), resulting in serious or fatal hemorrhage (e.g., cerebral, intracranial, and subdural hematoma) reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Risk of prolonged thrombocytopenia increased following each treatment phase in patients receiving gemtuzumab ozogamicin in combination with daunorubicin and cytarabine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor CBC counts prior to each dose, and more frequently following therapy until resolution of cytopenias.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor for manifestations of bleeding during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If hemorrhage or prolonged thrombocytopenia occurs, institute supportive care; treatment delay or discontinuance of therapy may be required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hematologic Toxicity under Dosage and Administration.)</p><p>Prolongation of QT interval reported in patients receiving other antibody-drug conjugates containing calicheamicin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor ECG and serum electrolytes prior to initiation of therapy and as clinically indicated in patients with a history of or predisposition to QT interval prolongation (e.g., those with electrolyte abnormalities or receiving concomitant drugs known to prolong the QT interval).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Subgroup analysis suggests a lack of clinical benefit for the drug in combination with standard therapy versus standard therapy alone in patients with unfavorable cytogenetics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider potential benefits and risks of continuing gemtuzumab ozogamicin in combination with daunorubicin and cytarabine in patients with newly diagnosed de novo AML following availability of cytogenetic test results.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Embryofetal toxicity and teratogenicity demonstrated in animals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Confirm pregnancy status prior to initiating therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid pregnancy during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Women of childbearing potential and men who are partners of such women should use effective contraceptive methods while receiving gemtuzumab ozogamicin and for ≥6 and ≥3 months, respectively, after the drug is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If used during pregnancy, apprise of potential fetal hazard.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May impair male and female fertility.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immunogenic potential not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Animal studies suggest possible fetal harm if used during pregnancy; no available data in pregnant women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><p>Not known whether distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Effects on nursing infants and milk production also unknown.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing during therapy and for ≥1 month after drug discontinuance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in pediatric patients with newly diagnosed AML.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use of gemtuzumab ozogamicin monotherapy for relapsed or refractory AML in pediatric patients ≥2 years of age is supported by a noncomparative study that included 13 patients 2 years to &lt;12 years of age and 15 patients 12–18 years of age; only 1 patient was &lt;2 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; No overall differences in safety and efficacy relative to age group observed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In the principal clinical trial evaluating gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for newly diagnosed de novo AML, no overall differences in safety or efficacy in geriatric patients (≥65 years of age) relative to younger adults observed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In the principal clinical study evaluating gemtuzumab ozogamicin monotherapy for newly diagnosed AML, all patients were ≥60 years of age; no overall differences in safety or efficacy based on age observed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In the principal clinical trial evaluating gemtuzumab ozogamicin monotherapy for relapsed or refractory AML, no overall differences in safety or efficacy in geriatric patients (≥65 years of age) relative to younger adults observed; however, pyrexia and infection of severe or greater severity occurred more frequently in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pharmacokinetics not affected by mild hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><p>Pharmacokinetics not affected by mild or moderate renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><h3>Common Adverse Effects</h3><p>Combination therapy with daunorubicin and cytarabine in patients with newly diagnosed de novo AML: Hemorrhage,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; infection,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; prolonged thrombocytopenia (platelet counts &lt;50,000/mm<sup>3</sup> lasting &gt;42 days in absence of active disease),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; anemia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; neutropenia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hypophosphatemia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hypokalemia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hyponatremia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; elevated alkaline phosphatase concentrations,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; elevated ALT and/or AST concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monotherapy in patients with newly diagnosed AML: Hepatotoxicity,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; fatigue,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; infection,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; cardiac effects,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hemorrhage,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; febrile neutropenia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; metabolic abnormalities.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monotherapy in patients with relapsed or refractory AML: Pyrexia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; infection,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; elevated ALT and/or AST concentrations,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hemorrhage,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; nausea and vomiting,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; constipation,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; mucositis,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; headache,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rash,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; sepsis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Gemtuzumab</h2><p>In vitro, gemtuzumab ozogamicin unlikely to inhibit CYP isoenzymes 1A2, 2A6, 2C8, 2C9, 2C19, 2D6, and 3A4/5 at clinically relevant concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In vitro, calicheamicin derivative of the antibody-drug conjugate unlikely to inhibit CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5 inhibit UGT 1A1, 1A4, 1A6, 1A9, and 2B7, or induce CYP isoenzymes 1A2, 2B6, and 3A4 at clinically relevant concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Calicheamicin derivative of the antibody-drug conjugate unlikely to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 2, organic anion transport protein (OATP) 1B1, and OATP1B3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No formal drug interaction studies have been performed to date.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Drugs that Prolong QT Interval</h3><p>Potential additive effect on QT-interval prolongation; manufacturer recommends ECG and electrolyte monitoring during concomitant use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Prolongation of QT Interval under Cautions.)</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Gemtuzumab Pharmacokinetics</h2><p>Formal pharmacokinetic studies not performed for fractionated doses of gemtuzumab ozogamicin (e.g., 3 mg/m<sup>2</sup> on days 1, 4, and 7).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Absorption</h3><p>Simulations suggest reduced peak plasma concentrations and systemic exposure of gemtuzumab ozogamicin when given in a fractionated dosing regimen (3 mg/m<sup>2</sup> on days 1, 4, and 7) compared with an unfractionated regimen (9 mg/m<sup>2</sup> for 2 doses administered 14 days apart).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hepatic impairment: No clinically meaningful effect on pharmacokinetics in patients with mild hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Data not available for moderate or severe hepatic impairment (total bilirubin concentration &gt;1.5 times the ULN).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Renal impairment: No clinically meaningful effect on pharmacokinetics in patients with mild or moderate renal impairment (Cl<sub>cr</sub> 30–89 mL/minute).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Data not available for severe renal impairment (Cl<sub>cr</sub> 15–29 mL/minute).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Not known whether gemtuzumab ozogamicin is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Calicheamicin derivative: Approximately 97%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Calicheamicin derivative extensively metabolized, primarily by nonenzymatic reduction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Unconjugated gemtuzumab: 62 and 90 hours following first and second doses, respectively, of antibody-drug conjugate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C in original package to protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reconstituted drug: 2–8°C for ≤1 hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diluted infusion solution: If not used immediately, may store at 2–8°C for ≤12 hours (including 1-hour storage of reconstituted solution in refrigerator, if needed, prior to dilution) and at room temperature (15–25°C) for ≤6 hours (including 2-hour infusion time and an additional 1 hour, if needed, to allow refrigerated diluted solution to reach room temperature prior to administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Sodium chloride 0.9%</p><h2>Actions</h2><ul>
<li>
<p>Antibody-drug conjugate consisting of an anti-CD33 antibody (recombinant humanized IgG<sub>4</sub> kappa immunoglobulin) conjugated with the cytotoxic antitumor antibiotic <i>N</i>-acetyl-γ-calicheamicin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Formulation consists of both conjugated and unconjugated antibody; on average, approximately 2–3 moles of the calicheamicin derivative are attached to each mole of antibody.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>The antibody-drug conjugate binds to antigen CD33, a transmembrane glycoprotein expressed on leukemic blasts in &gt;80% of patients with AML; resultant complex is internalized by the cell and the calicheamicin derivative is released via hydrolytic cleavage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The released calicheamicin derivative binds to DNA in the minor groove causing double-strand breaks and subsequent cell cycle arrest and apoptosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Saturation of a high percentage of antigen CD33 required for maximum delivery of calicheamicin to leukemic blast cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Near maximal saturation of antigen CD33 in peripheral blood observed with doses ≥2 mg/m<sup>2</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Antibody-drug conjugate consisting of an anti-CD33 antibody (recombinant humanized IgG<sub>4</sub> kappa immunoglobulin) conjugated with the cytotoxic antitumor antibiotic <i>N</i>-acetyl-γ-calicheamicin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Formulation consists of both conjugated and unconjugated antibody; on average, approximately 2–3 moles of the calicheamicin derivative are attached to each mole of antibody.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The antibody-drug conjugate binds to antigen CD33, a transmembrane glycoprotein expressed on leukemic blasts in &gt;80% of patients with AML; resultant complex is internalized by the cell and the calicheamicin derivative is released via hydrolytic cleavage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The released calicheamicin derivative binds to DNA in the minor groove causing double-strand breaks and subsequent cell cycle arrest and apoptosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Saturation of a high percentage of antigen CD33 required for maximum delivery of calicheamicin to leukemic blast cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Near maximal saturation of antigen CD33 in peripheral blood observed with doses ≥2 mg/m<sup>2</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Risk of hepatotoxicity, including severe, life-threatening, or fatal hepatic VOD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing patients that the risk of developing hepatic VOD may be increased in patients who have previously undergone or plan to undergo HSCT.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of regular monitoring for signs and symptoms of hepatotoxicity (e.g., rapid weight gain, right upper-quadrant abdominal pain or tenderness, hepatomegaly, ascites) during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of thrombocytopenia and hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinicians if signs and symptoms of bleeding occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of infusion-related reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of reporting signs and symptoms of such reactions, including fever, chills, rash, or breathing difficulty.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of childbearing potential and men who are partners of such women that they should use an effective method of contraception while receiving the drug and for ≥6 and ≥3 months, respectively, after discontinuance of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinicians if they are or plan to become pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If pregnancy occurs, advise pregnant women of potential risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising women to discontinue nursing during therapy and for ≥1 month after discontinuance of the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Risk of hepatotoxicity, including severe, life-threatening, or fatal hepatic VOD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing patients that the risk of developing hepatic VOD may be increased in patients who have previously undergone or plan to undergo HSCT.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of regular monitoring for signs and symptoms of hepatotoxicity (e.g., rapid weight gain, right upper-quadrant abdominal pain or tenderness, hepatomegaly, ascites) during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of thrombocytopenia and hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinicians if signs and symptoms of bleeding occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of infusion-related reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of reporting signs and symptoms of such reactions, including fever, chills, rash, or breathing difficulty.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of childbearing potential and men who are partners of such women that they should use an effective method of contraception while receiving the drug and for ≥6 and ≥3 months, respectively, after discontinuance of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinicians if they are or plan to become pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If pregnancy occurs, advise pregnant women of potential risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising women to discontinue nursing during therapy and for ≥1 month after discontinuance of the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For injection, for IV infusion</p><p>4.5 mg</p><p>Mylotarg<sup></sup></p><p>Wyeth</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions October 15, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Wyeth. Mylotarg<sup></sup> (gemtuzumab ozogamicin) for injection prescribing information. Philadelphia, PA; 2018 Apr. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05</p><p>2. Amadori S, Suciu S, Selleslag D et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>J Clin Oncol</i>. 2016; 34:972-9. http://www.ncbi.nlm.nih.gov/pubmed/26811524?dopt=AbstractPlus</p><p>3. Food and Drug Administration. Search orphan drug designations and approvals. From FDA website. Accessed 2019 May 18. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm</p><p>5. Battipaglia G, Labopin M, Candoni A et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplant</i>. 2017; 52:592-599. http://www.ncbi.nlm.nih.gov/pubmed/28092357?dopt=AbstractPlus</p><p>6. Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. <i>Blood</i>. 2017; 130:2373-2376. http://www.ncbi.nlm.nih.gov/pubmed/29021230?dopt=AbstractPlus</p><p>7. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). <i>J Clin Exp Hepatol</i>. 2014; 4:332-46. http://www.ncbi.nlm.nih.gov/pubmed/25755580?dopt=AbstractPlus</p><p>8. Amadori S, Suciu S, Selleslag D et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). <i>Br J Haematol</i>. 2010; 149:376-82. http://www.ncbi.nlm.nih.gov/pubmed/20230405?dopt=AbstractPlus</p><p>9. Olombel G, Guerin E, Guy J et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. <i>Blood</i>. 2016; 127:2157-60. http://www.ncbi.nlm.nih.gov/pubmed/26929274?dopt=AbstractPlus</p><p>10. Food and Drug Administration. Center for Drug Evaluation and Research (CDER): Oncologic Drugs Advisory Committee (ODAC) meeting. Silver Spring, MD; 2017 Jul 11. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm567363.pdf</p><p>11. Food and Drug Administration. Gemtuzumab ozogamicin. Silver Spring, MD; 2010 Jun 21. From FDA website. http://wayback.archive-it.org/7993/20161024005421/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm216790.htm</p><p>12. Shapiro M. Dear healthcare professional letter: Pfizer prepares for voluntary withdrawal of US New Drug Application and for discontinuation of commercial availability of Mylotarg for relapsed acute myelogeneous leukemia. New York, NY: Pfizer; 2010 Jun 21. https://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf</p><p>13. Report of study: S0106 Phase III. Presented at Southwest Oncology Group spring group meeting. San Francisco, CA: 2010 Apr 17. http://www.swogstat.org/ros/rosbooks/spring%202010/leukemia.pdf</p><p>14. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. <i>Leukemia</i>. 2017; 31:1855-1868. http://www.ncbi.nlm.nih.gov/pubmed/28607471?dopt=AbstractPlus</p><p>15. Food and Drug Administration. FDA briefing document: Oncologic drugs advisory committee meeting. Silver Spring, MD; June 2017. From FDA web site. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm566013.pdf</p><p>16. Wyeth Pharmaceuticals. Mylotarg<sup></sup> (gemtuzumab ozogamicin) for injection prescribing information. Philadelphia, PA; 2001 Jul.</p><p>17. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. <i>Ther Adv Hematol</i>. 2015; 6:253-61. http://www.ncbi.nlm.nih.gov/pubmed/26425338?dopt=AbstractPlus</p><p>20. Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. <i>Leuk Res</i>. 2016; 44:61-4. http://www.ncbi.nlm.nih.gov/pubmed/27030962?dopt=AbstractPlus</p><p>21. Burnett A, Cavenagh J, Russell N et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m<sup>2</sup> with 6 mg/m<sup>2</sup> in the NCRI AML17 Trial. <i>Haematologica</i>. 2016; 101:724-31. http://www.ncbi.nlm.nih.gov/pubmed/26921360?dopt=AbstractPlus</p><p>22. Cowan AJ, Laszlo GS, Estey EH et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Front Biosci (Landmark Ed)</i>. 2013; 18:1311-34. http://www.ncbi.nlm.nih.gov/pubmed/23747885?dopt=AbstractPlus</p><p>23. Jen EY, Ko CW, Lee JE et al. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. <i>Clin Cancer Res</i>. 2018; http://www.ncbi.nlm.nih.gov/pubmed/29476018?dopt=AbstractPlus</p><p>24. Pfizer, Philadelphia, PA: Personal communication.</p><p>25. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 761060Orig1s000/761060Orig2s000: Summary Review. From FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000SumR.pdf</p><p>26. Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet</i>. 2012; 379:1508-16. http://www.ncbi.nlm.nih.gov/pubmed/22482940?dopt=AbstractPlus</p><p>27. Tallman MS, McDonald GB, DeLeve LD et al. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. <i>Int J Hematol</i>. 2013; 97:456-64. http://www.ncbi.nlm.nih.gov/pubmed/23460018?dopt=AbstractPlus</p><p>28. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 761060Orig1s000/761060Orig2s000: Clinical Review. From FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000MedR.pdf</p><p>29. Wyeth Pharmaceuticals. Besponsa<sup></sup> (inotuzumab ozogamicin) for injection prescribing information. Philadelphia, PA; 2017 Aug. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077</p><h2>More about gemtuzumab</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: CD33 monoclonal antibodies</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gemtuzumab Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Myeloid Leukemia</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>